Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Private Credit Sees Rise in Acceptance For DC Plan Portfolios

BY | ETF Database
7:39 am ET 06/24/26 | 11 VIEWS
  • Related Symbols
  • PCR
The pathways into Defined Contribution (DC) plans could be opening up for private credit. According to PIMCO’s 2026 Defined Contribution Consulting Study, private market asset classes are starting to gain greater acceptance within default funds.Based on survey responses from 38 consulting and advisory firms, the expectation is that plan sponsors are willing to adopt private market exposure in target-date funds (TDFs) or managed accounts within the next year. This constitutes a massive surge from just 37% in the prior year’s study.Key Takeaways: PIMCO’s 2026 study reveals that a massive 89% of plan sponsors are now willing to adopt private market exposure in target-date funds or managed accounts within the next year. Previously, that number was 37%. Private credit ranks as the most sought-after private asset class for defined contribution plans, with intermediaries prioritizing high returns balanced against cost, asset quality, and daily liquidity. The Simplify Private Credit Strategy ETF (PCR) bridges this gap by packaging institutional private lending into a transparent, liquid vehicle with a competitive 0.76% expense ratio. See more: From Institutional to Public Portfolios: Access Private Credit With PCRAccess Private Credit With Daily LiquidityThe PIMCO study noted that 91% of aggregators and 52% of institutional consultants rank private credit among the most likely private assets slated for addition to DC multi-asset funds in the near term. As broader adoption unfolds, intermediaries are heavily emphasizing the need to balance high return potential with cost, asset quality, and the strict requirement to maintain daily liquidity. Enter exchange-traded funds (ETFs), which have helped to democratize access to private credit. Access to this market historically meant dealing with lock-up periods, complex tax reporting, and high management fees. The +Simplify Private Credit Strategy ETF+ (PCR) clears these structural hurdles by packaging private credit access into a transparent, liquid investment vehicle.Income and Capital AppreciationPCR’s primary investment objective is to generate income and capital appreciation. PCR actively utilizes the VettaFi Private Credit Index (VPCIX), which screens public business development companies (BDCs) and closed-end funds (CEFs) that have at least 50% of their portfolios directly tied to private corporate lending. By utilizing total return swaps to provide this exposure, the fund maintains daily liquidity along with a highly competitive net expense ratio of 0.76%. This is drastically lower than standard fund-of-CEF strategies. The active mandate in PCR empowers its portfolio managers to implement real-time credit underwriting and manager selection. As such, PCR can dynamically tilt its asset allocation toward top-tier institutional private credit managers in various macroeconomic conditions. As plan sponsors demand more access to private credit solutions, PCR offers a liquid and cost-efficient solution. The fund bridges the gap between high-yielding private debt and the liquid operational needs of modern portfolios, making it a compelling tool as demand for private credit boom increases. For more news, information, and analysis, visit the Institutional Income Strategies Content Hub. VettaFi LLC (“VettaFi”) is the index provider for PCR, for which it receives an index licensing fee. However, PCR is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of PCR.

More Commentary

How IBUY Taps Into Prime Day's Online Retail Boom
BY | ETF Database
8:05 am ET 06/24/26 | 6 VIEWS
State Street Goes Heads Up With Qs, Launches Nasdaq 100 ETF
BY | ETF Database
8:48 am ET 06/24/26 | 3 VIEWS
Long-Term Outlook Brightens for This Nuclear ETF
BY | ETF Database
6:10 am ET 06/24/26 | 32 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.

Down Homepage
customer service
Customer
Service
trade
Trade

Contact us:

chat Chat with a
representative
building Find an Investor
Center

Reference Number:

950994.2.0

call Page Pixel